

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
J. Vernon Knight *et al.*

Serial No.: 10/663,573

Filed: September 16, 2003

For: SMALL PARTICLE LIPOSOME
AEROSOLS FOR DELIVERY OF
ANTICANCER DRUGS

Group Art Unit: 1615

Examiner: Unknown

Atty. Dkt. No.: CLFR:158US

Confirmation No.: 2987

CERTIFICATE OF ELECTRONIC SUBMISSION

DATE OF SUBMISSION: December 29, 2005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. § 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. § 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/CLFR:158US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

David L. Parker
Reg. No. 32,165
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: December 29, 2006

Form PTO-1449 (modified)		Atty. Docket No. CLFR:158US	Serial No. 10/663,573
List of Patents and Publications for Applicant's		Applicant J. Vernon Knight <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: September 16, 2003	Group: 1615
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B6	WO 98/00111	01/08/98	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C28	Burke, "Lipid bilayer partitioning and stability of camptothecin drugs," <i>Biochemistry</i> , 32:5352-5364, 1993.
	C29	Hinz <i>et al.</i> , "Pharmacokinetics of the <i>in Vivo</i> and <i>in Vitro</i> Conversion of 9-Nitro-20(S)-camptothecin to 9-Amino-20(S)-camptothecin in Humans, Dogs, and Mice," <i>Cancer Res.</i> , 54:3096-3100, 1994.

25730388.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.